A PYMNTS Company

US: Diagnostic company Exact Sciences to buy Genomic Health in $2.8B deal

By  |  July 29, 2019

Exact Sciences said on Monday it will buy peer Genomic Health for about $2.8 billion in cash and stock, expanding the cancer diagnostic company’s testing capabilities to breast and prostate cancers.

The deal will bring together Exact Sciences’ non-invasive stool screening test for colorectal cancer Cologuard, and Genomic Health’s Oncotype diagnostic tests for various cancers.

Genomic Health would help expand Exact Sciences’ focus from screening into treatment selection as well as monitoring, which are highly attractive markets, Canaccord Genuity analyst Mark Massaro said.

Full Content: Reuters

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.